HeartSciences (HSCS) to Post Earnings on Thursday

Posted by Stanley Muller on Sep 8th, 2026

HeartSciences (NASDAQ:HSCS – Get Free Report) is projected to release its Q1 2027 results before the market opens on Thursday, September 10th. Analysts expect the company to post earnings of ($0.72) per share and revenue of $0.10 million for the quarter. Interested persons can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Friday, September 18, 2026 at 4:00 PM ET.

HeartSciences (NASDAQ:HSCS – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). On average, analysts expect HeartSciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

HeartSciences Stock Performance

Shares of HeartSciences stock opened at $3.73 on Tuesday. The firm has a market cap of $14.55 million, a PE ratio of -0.95 and a beta of 1.85. The business’s 50 day simple moving average is $2.59 and its 200 day simple moving average is $2.36. HeartSciences has a 52-week low of $1.63 and a 52-week high of $3.83.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Check Out Our Latest Analysis on HSCS

Institutional Trading of HeartSciences

A hedge fund recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences as of its most recent filing with the Securities & Exchange Commission. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

About HeartSciences

(Get Free Report)

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.